Elidel® (pimecrolimus 1%) is as effective as TCS
Elidel® (pimecrolimus 1%) showed to be equally effective
Elidel® (pimecrolimus 1%) showed to be equally effective compared to low-to–medium potency topical corticosteroids to treat AD including sensitive skin areas. The Petite study is the longest open-label, randomized study done comparing topical corticosteroid treatment involving 2,439 pediatric patients with mild-to–moderate atopic dermatitis.
To read more, please click below.
Elidel® (pimecrolimus 1%) is as effective as TCS
NON-2023-11095-16NOV2023
Featured Contents
Long-term management of AD is needed
EU guidelines recommended not to use topical corticosteroid
Treatment algorithm in South and East Asia for mild-to-moderate AD
A panel of experts have proposed a practical algorithm
